Crescent Biopharma, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Waltham, MA
CBIO chart
What traders are saying about $CBIO
Latest postsCrescent Biopharma, Inc. news
- Crescent Biopharma, Inc. Estimates – NASDAQ:CBIO
TradingView ·
- Crescent Biopharma (CBIO) Edges Lower to $13.14 as Shares Consolidate Below Resistance - Buffered ETF
www.dars.gov.et ·
- Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001
Yahoo Finance ·
- Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
Yahoo Finance ·
- Crescent Biopharma Announces Grants of Inducement Awards
Yahoo Finance ·
- Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
Yahoo Finance ·
- Crescent Biopharma to Present at September Investor Conferences
Yahoo Finance ·
- Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Yahoo Finance ·
- Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Yahoo Finance ·
- Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
Yahoo Finance ·
- Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
Yahoo Finance ·
- Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
Yahoo Finance ·
Crescent Biopharma, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $10.8M | – | – | – |
| Net income | $153,942 | $37,879 | $36,899 | -$46.7M |
| Diluted EPS | – | $-0.59 | $-0.58 | $-0.89 |
| Total assets (year end) | $240.3M | $35.6M | $45.3M | $51.8M |
| Cash and equivalents (year end) | $213.2M | $34.8M | $41.8M | $47.9M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Crescent Biopharma, Inc.
- Ticker
- CBIO (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Waltham, MA
- Incorporated in
- Cayman Islands
- Fiscal year end
- December 31
- SEC CIK
- 1253689
- Former names
- GLYCOMIMETICS INC
Frequently asked questions
What exchange is Crescent Biopharma, Inc. listed on?
Crescent Biopharma, Inc. trades on the Nasdaq under the ticker symbol CBIO.
What industry is Crescent Biopharma, Inc. in?
Crescent Biopharma, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Crescent Biopharma, Inc. headquartered?
Crescent Biopharma, Inc.'s business address on file with the SEC is in Waltham, MA.
When does Crescent Biopharma, Inc.'s fiscal year end?
Crescent Biopharma, Inc.'s fiscal year ends on December 31.
How much revenue did Crescent Biopharma, Inc. report?
Crescent Biopharma, Inc. reported $10.8M in revenue for calendar year 2025, according to its SEC filings.